PVLA.US Palvella Therapeutics, Inc

Healthcare Biotechnology USA Stocks
144.35 USD
Close of Nov 18, 2026
72.23 179.95
Market cap
USD 2.11B
P/E
-
P/B
10.68x
ROE
-42.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PVLA.US undervalued?

Graham number

The Graham number of Palvella Therapeutics, Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Palvella Therapeutics, Inc fundamental analysis

No fundamental analysis for Palvella Therapeutics, Inc yet.

Palvella Therapeutics, Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Palvella Therapeutics, Inc

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN ra…

Full company profile